Results. The well-known Schwartz equation [eGFR = kL/Scr, k = 0.413 (Schwartz) or k = 0.373 (Schwartz-Lyon)] for children between 1 and 14 years can be seen as a special case of the new equation for which the Q-polynomial is simplified to a linear equation: Q = 0.0035 × L (cm). The new eGFR equation has been validated in a data set of n = 750 children, adolescents and young adults aged 10-25, against the true GFR (inulin method), and outperforms the selected (but most used) creatinine-based eGFR equations for children, mainly in the healthy GFR region. Conclusions. The new Q(height)-eGFR equation serves as an excellent screening tool for kidney disease in 1-25-year-old children, adolescents and young adults.
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I N T RO D U C T I O N
The glomerular filtration rate (GFR) is widely considered the best overall index of kidney function in health and disease. Because direct measurements of GFR cannot always be performed in clinical routine settings, formulas have been presented to estimate the GFR (eGFR) [1] . In those formulas, serum creatinine (Scr, expressed in mg/dL) is most commonly used as a marker for renal function.
In the last decade, new eGFR formulas have been developed for adults and children because of the evolution in laboratory testing of Scr to iotope dilution mass spectrometry (IDMS)-standardized techniques, but few attempts have been undertaken to develop new formulas for adolescents. Selistre et al. [2] assessed multiple existing adult and pediatric creatinine-based eGFR equations in adolescents and young adults, using inulin clearance as the reference method. The adult eGFR formulas substantially overestimate the GFR, but better prediction performance was found for the pediatric equations [3, 4] . (An overview of the pediatric equations used in this study is given in Table 1 ). Selistre et al., therefore, recommend the use of pediatric equations, especially the updated Schwartz equation to estimate the GFR from childhood to early adulthood.
However, none of the pediatric equations have been developed to be used in the adolescent population. Moreover, these formulas do not differentiate between boys and girls, although there is an important difference in growth (height) and in Scr concentration between sexes ever since adolescence. This large variation in body shape and growth determines extreme variation in muscular mass and may be a dominant factor when developing eGFR formulas for this population.
In this paper, we demonstrate how a new eGFR formula for adolescents is constructed from a particular rationale, based on the knowledge of Scr for healthy adolescents, combined with the use of metadata [5, 6] . This rationale uses the concept of population-normalized Scr in which the normalization constant (Q) is the median or the average Scr concentration of a specific population of healthy people, be it children or adults [7] [8] [9] . It has been shown that for adults between 18 and 65 years of age, the value of Q is a constant and equals 0.70 mg/dL for Caucasian females and 0.90 mg/dL for Caucasian males [10] . For children, Q is the median Scr for healthy children and depends linearly on age [7] . We extended this idea of normalized Scr to adolescents. By modeling Q as a function of age, we experienced different relationships for girls and boys, but when modeling Q as a function of height, we found a unique relationship between Q and height for both boys and girls. This Q(height) relationship forms the basis for a promising new eGFR equation suitable for children, adolescents and even young adults.
M AT E R I A L S A N D M E T H O D S

Databases
In order to define Q-values (the median Scr for healthy children and adolescents), we used a data set of 15 978 subjects aged between 0.1 and 20 years from AZ Groeninge Hospital in Kortrijk, Belgium. This data set contains Scr-values, age and sex of the patients, which allowed to calculate the Q values as a function of age. To evaluate the height dependency of Q, we used the national growth curves [11] . Once the new eGFR formulas for children and adolescents were created (one formula with age-dependent Q-values and one formula with height-dependent Q-values), an independent database was used for the Table 1 . Overview of eGFR equations
GFR estimating equations Formula
Schwartz-Lyon equation [2] eGFR ¼ kL=Scr k ¼ 0:419 if males aged . 13 year k ¼ 0:373 otherwise Updated Schwartz IDMS equation [3] eGFR ¼ eGFR ¼ kL=Scr k ¼ 0:413 Simple height-independent equation (Simple) [7] eGFR ¼ 107:3=ðScr=QÞ Q ¼ 0:0270 Â Age þ 0:2329 FM equation [14] eGFR ¼ eGFR ¼ kL=Scr k ¼ 0:0414 Â lnðAgeÞ þ 0:3018 Q(age) equation (this is an extension of the simple heightindependent equation [7] 
for boys and girls
L, height in cm or in Q(height) equation, m; Scr, serum creatinine in mg/dL, age in years.
O R I G I N A L A R T I C L E
N e w e G F R e q u a t i o n validation. This database, which contains 750 unique inulin measurements in children, adolescents and young adults aged between 10 and 25, was previously used by Selistre et al. [2] . Characteristics of the database can be found in Table 2 .
Scr and GFR measurements
The Scr data of AZ Groeninge Hospital were obtained with the Roche enzymatic assay, described in Pottel et al. [10] . The enzymatic method was considered IDMS-standardized. In the validation database, Scr was determined with the Roche compensated Jaffe assay. The Scr measurements obtained by the compensated Jaffe assay were standardized by linear regression adjustment to concentrations obtained by liquid mass chromatography as described in Selistre et al. [2] . Since the enzymatic method used to design our equations has been calibrated against the IDMS method, and since all compensated Jaffe Scr results in the validation database were calculated back to the gold standard method, both Scr concentrations in the design and validation step of our study are considered equivalent.
In the validation database, the GFR was measured by the renal clearance of inulin ( polyfructosan, Inutest; Fresenius Kagi, Graz, Austria) [2] . A standard technique was used by trained staff with a continuous infusion after a priming dose of 30 mg/kg polyfructosan. Water diuresis was induced by oral administration of 5 mL/kg of water followed by 3 mL/kg every 30 min combined with an intravenous infusion of 0.9% sodium chloride. This enabled the patients to spontaneously empty their bladder every 30 min. Three to four urine samples were collected and a blood sample was drawn mid-way to each collection period. The clearance values were calculated from the mean values of the three to four clearance periods. Serum and urine polyfructosan measurements were performed using the enzymatic method (within-run precision < 1% and between-run precision < 3.5%) described by Dubourg et al. [12] . The results were corrected for the body surface area according to the formula of Dubois and Dubois [13] .
Statistical analyses
Descriptive statistics, polynomial regression, Bland-Altman analysis, exact McNemar's test, paired t-test and all graphs were performed in Graphpad Prism 6.0 (La Jolla, CA, USA) or SAS 9.3 (SAS Institute Inc., Cary, NC, USA). Statistical significance is presented when P < 0.05. No correction was performed for multiple comparisons.
A performance score for the eGFR formulas was calculated, based on the following rules:
(i) absolute bias <5: score = score + 5; absolute bias between 5 and 10: score = score + 3; absolute bias between 10 and 15: score = score + 1,
(ii) within 30% >80%: score = score + 5; within 30% is between 70 and 80%: score = score + 3; within 30% is between 60 and 70%: score = score + 1 (iii) within 10% >40%: score = score + 5; within 10% is between 30 and 40%: score = score + 3; within 10% is between 20 and 30%: score = score + 1.
R E S U LT S
New eGFR formulas for adolescents
The AZ Groeninge Hospital data set was used to model the Scr of 15 978 children and adolescents between 0.1 year and 20 years as a function of age, separately for boys and girls ( Figure 1A and B). Figure 2A shows the median data only, without the individual subject values. These figures demonstrate that the median Scr for boys and girls evolves equivalently from birth till ∼13 years of age and then gradually starts to diverge. In a first attempt to build a new eGFR model for adolescents, the model eGFR = 107.3/(Scr/Q) with age-dependent Q-values for boys and girls (an extrapolation of the simple height-independent formula for children [7] ) was presented. However, we observed large growth differences between adolescents and young adults of the same age and therefore we also modeled Q as a function of height and used this Q(height) relationship in the above presented eGFR formula. The median height of healthy children and adolescents (aged between 0.1 and 20) was obtained from the national growth curves [11] . The median Scr was fitted against age, resulting in a Q(age) relationship ( Figure 2A ) which differs for boys and girls. The median Scr was also fitted against height, resulting in a unique Q(height) relationship ( Figure 2B ). In both cases, a fourth-degree polynomial was required to adequately fit the Q data. The fourth-degree polynomials for Q are: Piepsz et al. [5, 6] showed that after maturation of the kidneys, the true GFR for healthy children stabilizes to the median value of 107.3 mL/min/1.73 m 2 , a value we used previously to present a general form for an eGFR formula for children: eGFR = 107.3/(Scr/Q) [7] . Building further on this concept, and using the polynomials for Q, this leads to two new eGFR formulas with age-dependent
Validation of the new equations To validate our new formulas, we used an independent data set containing measured GFR (mGFR) (inulin method). We present comparisons between our new equations and mGFR and with four other pediatric equations (Table 1) : the updated Schwartz [3] , the Schwartz-Lyon [4] , the simple height-independent (Simple) [7] and the Flanders metadata (FM) [14] equation. The comparisons were performed in three different age-subgroups: 10-14-year-old children, 14-18-year-old adolescents and 18-25-year-old young adults.
Accuracy expressed as within 10 and 30% of the mGFR and bias calculations in the different age-subgroups for mGFR <60 mL/min/1.73 m 2 , between 60 and 90 and >90 mL/min/ 1.73 m 2 are summarized in Table 3 . Differences between mGFR and eGFR for the whole cohort are visualized in Bland-Altman plots in Figure 3 .
A performance score for the six different eGFR formulas (Table 1) in each subgroup (defined by mGFR <60 mL/min/ 173 m 2 , mGFR between 60 and 90 mL/min/1.73 m 2 and mGFR >90 mL/min/1.73 m 2 and by age: 10-14, 14-18 and >18 years old) and for the overall cohort was calculated. Results of the scoring system can be found in Table 3 . 
O R I G I N A L A R T I C L E
N e w e G F R e q u a t i o n In the mGFR subgroup <60 mL/min/1.73 m 2 , the Schwartz-Lyon equation gets the highest score (score = 35), followed by comparable results for the updated Schwartz (score = 25), the Q(height) (score = 24) and the FM (score = 23) equation. In the mGFR subgroup between 60 and 90 mL/ min/1.73 m 2 , the FM equation (score = 39) and the SchwartzLyon (score = 39) have the best results, closely followed by Q (height)-eGFR (score = 37). In the mGFR subgroup >90 mL/ min/1.73 m 2 , Q(age)-eGFR (score = 43) gets the highest score, closely followed by Q(height)-eGFR (score = 41) and by the Simple equation (score = 41). When the overall score is calculated, the new Q(height) equation (score = 102) shows the best score, followed by the FM formula (score = 99), the SchwartzLyon equation (score = 97), the updated Schwartz equation (score = 92), the Simple formula (score = 73) and Q(age)-eGFR (score = 68). The Q(height) equation is therefore the best generally applicable eGFR equation for children, adolescents and young adults and outperforms the other heightdependent equations especially in the GFR >60 mL/min/ 1.73 m 2 region. Weight categories were defined based on international cutoff points for body mass index (BMI) for thinness grades 1 (very severely underweight), 2 (severely underweight) and 3 (underweight) [15] , overweight and obesity [16] 
Because the subgroups 'severely underweight' and 'very severely underweight' only contained 6, 9, 7 and 4, 1, 4 children, adolescents and young adults, respectively, we pooled all underweight patients in the 'underweight' subgroup, corresponding to one subgroup for thinness grades 1, 2 and 3.
If the bias, the within 10% and the within 30% accuracies in the overweight, the normal weight and the underweight children, adolescents and young adults are calculated (Table 4) , then an increased bias and lower accuracies in the underweight patients can be noticed, especially when the age-based eGFR formulas [Simple formula and Q(age) equation] are used. The Q(height)-eGFR formula still gives good results in the underweight subjects. The Schwartz-Lyon equation seems to perform better in the underweight than in the overweight patients.
In the validation cohort, 123 transplant patients are included for which bias, within 10 and within 30% accuracies of the various eGFR models were calculated ( Table 5 ). The bias of the Schwartz equation, the FM formula and Q(height)-eGFR are not significantly different from zero (P > 0.05). The results for the renal graft patients do not differ from the results in the whole cohort, especially when compared with the overall subgroup mGFR between 60 and 90 mL/min/1.73 m 2 (Table 3) .
D I S C U S S I O N
There are many creatinine-based formulas to estimate the GFR for children, including the Schwartz formula [3] , the Schwartz-Lyon equation [4] , the FM formula [14] , the Simple equation [7] , the Lund-Malmö formula [17] , the Léger equation [18] , the BCCH1 equation [19] and the formula of Zappitelli [20] . However, there is no formula especially designed for adolescents. Recently, Selistre et al. [2] recommend the use of pediatric formulas, especially the updated Schwartz formula, to estimate the GFR in the adolescent and young adult population. However, these pediatric formulas have not been designed for use in adolescents or young adults, but they outperform the MDRD [21] and CKD-EPI [22] equations for adults.
During adolescence, like in children, Scr increases with height ( Figure 2B ), although no longer in a linear way. This simultaneous increase in Scr and height might be the reason why the updated Schwartz equation (eGFR = kL/Scr) still gives reasonable results in adolescents (Table 3) . However, there has never been an adaptation of the constant k = 0.413 in the updated Schwartz equation for adolescents, although Schwartz made the adaptation in the original equation from 0.55 to 0.70 for adolescent boys, showing the need for adjustments in the formulas for adolescents [23, 24] .
In this study, we developed a new eGFR formula for children and adolescents based on the concept of population-normalized Scr where the normalization constant (Q) may be
The median Scr (in mg/dL) as a function of age (A) and as function of median height (B) for boys (bullets) and girls (squares). The first part (for heights between 76 and 166 cm, corresponding to children between 1 and 14 years of age) of the curve in (B) can be linearly modeled as Q = 0.0035 × L. 
Continued
O R I G I N A L A R T I C L E
N e w e G F R e q u a t i o n . Bias is calculated as mGFR -eGFR. Equal letters in each row denote statistically significant differences (P < 0.05, exact McNemar's test). *Denotes statistically significant difference between eGFR and mGFR (P < 0.05, paired t-test). **The SCORE is the sum of the scores of the bias, the within 30% and the within 10% of all age subgroups within a specific mGFR subgroup. ***The OVERALL SCORE is the sum of the SCORES of the three mGFR subgroups.
seen as the Scr concentration of the average healthy person in a specific population, equivalent to what has been described previously for children and adults [7] [8] [9] . For adults between 18 and 65 years of age, a CKD-EPI-like equation with a constant value Q (0.70 mg/dL for Caucasian females and 0.90 mg/dL for Caucasian males) has been proposed [8, 9] . Recently, the Simple eGFR equation for children, based on the same concept, was published [7] . For children, Q depends linearly on age (Q = 0.0270 × Age + 0.2329). In the current study, we extended the use of Scr/Q to adolescents in two possible Within 30%, Simple height-independent eGFR and Q(age)-eGFR are significantly different from the other percentages within the row. Within 10%, Q(age)-eGFR is significantly different from FM eGFR and from Schwartz-Lyon eGFR. *Statistically significant difference between eGFR and mGFR (P < 0.05, paired t-test).
N e w e G F R e q u a t i o n ways: with Q the Scr for the average healthy child or adolescent of a specific age or with Q as the Scr of the average healthy child or adolescent of a specific height. The Scr/Q concept can now be used for different age classes: for children [7] , adolescents and adults [8] . For adults, race and sex information is included in the value of Q. By normalizing Scr by Q, Scr/Q becomes independent of age, race and sex [8, 25] . After the development of the two new formulas, they were compared with the mGFR and with the updated Schwartz, the Schwartz-Lyon, the Simple and the FM equation (Table 1) . The Schwartz-Lyon equation is a locally adapted form of the original Schwartz formula [24] . With a small age-dependent modification of the updated Schwartz constant, the FM equation was developed, which can be used to estimate the GFR in infants (aged >1 month) and children up to 14 years of age. The Simple equation is valid for children between 1 and 14 years. All these pediatric equations were applied to subgroups of children, adolescents and young adults.
The Schwartz-Lyon equation performs better than all other equations in the mGFR <60 mL/min/1.73 m 2 range, closely followed by the Schwartz, the FM and the Q(height) equation (Table 3 ). This also shows that height-dependent equations perform better than age-dependent equations in this subgroup, and this is true for all age-categories (children, adolescents and young adults). In the 60-90 mL/min/1.73 m 2 subgroup, the Schwartz-Lyon equation still gives the best results for children and adolescents, but the Q(height)-eGFR equation gives the best results in young adults. Finally, the age-dependent extension of the Simple equation gives the best predictions in the mGFR >90 mL/min/1.73 m 2 subgroup, very closely followed by the Q (height)-eGFR method, for all age-categories. The good performance of the Q(height)-eGFR equation in healthy subjects is not surprising, as this equation has been designed with data of healthy children and adolescents. Note also that the SchwartzLyon equation is the worst performer in this mGFR subgroup. Although making a ranking of performance of the different eGFR is not straightforward, we tried to do so by calculating a performance score using three specific but rather arbitrary criteria as described in the 'Materials and methods' section. When the overall performance score of the six pediatric equations is calculated, the Q(height)-eGFR gives the highest overall score (Table 3) .
The overall performance of the Q(height)-eGFR method is such that it can be used as a first screening tool which is reliable when the obtained eGFR is higher than 60 mL/min/1.73 m 2 . In case the eGFR result is below 60 mL/min/1.73 m 2 , a better estimation would be obtained from the Schwartz-Lyon equation and probably it would be advisable to do a direct measurement in that case.
The new Q(height) equation [eGFR = 107.3/(Scr/Q)] is not a revolution and still lacks precision, the problem with all eGFR equations, but this equation is not just based on pure statistical modeling, but on a specific rationale, emphasizing the relation between GFR and Scr. Departure of Scr/Q from '1', the situation for the average healthy child, also leads to the departure of eGFR from 107.3 mL/min/1.73 m 2 .
The new Q(height)-eGFR equation is also more broadly applicable than the other pediatric formulas, since the Q(height) formula can be used to estimate the GFR in children, adolescents and even in young adults up to 25 years of age (Table 3) . Selistre et al. [2] has shown that the Schwartz or the Schwartz-Lyon equation already performs better in young adults than adult eGFR equations like the MDRD [21] or the CKD-EPI [22] equation. This study shows that in young adults with an mGFR >60 mL/min/1.73 m 2 , the Q(height)-eGFR performs even better than the Schwartz or the Schwartz-Lyon equation. Moreover, the updated Schwartz equation for children between 1 and 14 years of age can be seen as a special case of the Q(height) equation, for which the normalization value Q is linearly dependent on the height of the child (Q = 0.0035 × L, R 2 = 0.975, with 76 cm < L < 166 cm). By introducing the result Q = 0.0035 × L in our equation eGFR = 107.3/ (Scr/Q), this becomes eGFR = 107.3 × 0.0035 × L/Scr = 0.376 × L/Scr. The value of 0.376 is also the average in the age region [1-14 years] of 0.0414 × ln(age) + 0.3018, the age-dependent k-value in the FM equation [14] , and is also very close to the value of 0.373 determined by the research group in Lyon (k = 0.373) for children aged ≤13 years [4] and only a little smaller than k = 0.413 of the Schwartz equation [3] . This shows that the Q(height) equation is mathematically equivalent to the Schwartz and/or Schwartz-Lyon and/or the FM equation for children between 1 and 14 years of age. Therefore, the alternative Q(height)-eGFR equation [eGFR = 107.3/(Scr/Q)] can be considered as validated for children between 1 and 14 years of age as well.
The database of n = 750 children, adolescents and young adults contained a considerable subgroup of underweighted patients. The increased bias in the underweight patients, especially when using the age-based eGFR formulas, can be seen in Table 4 . On the other hand, the new Q(height)-eGFR formula still gives reasonable results in the underweight patients, probably because weight and height are highly correlated and underweight mostly goes together with retarded growth. Based on this study, height is a good indicator for 'muscle mass' and related to that for growth and age.
De Souza et al. [26] previously evaluated if the Schwartz and the Schwartz-Lyon equation are applicable to kidney transplant patients. They reported results that were similar to those found in non-transplanted patients. Our study confirms that all pediatric equations studied here, give results in transplant patients ( Table 5 ) that are comparable with the overall 750 patients (Table 3) .
In summary, the new Q(height)-eGFR equation is applicable to estimate the GFR in children (1-14 years), in adolescents (14-18 years) and even in young adults up to 25 years of age. The Q(height)-eGFR formula performs best in healthy patients, but a low predicted Q(height)-eGFR result may serve as a warning sign for kidney disease. The new Q(height)-eGFR equation can thus be considered as an excellent screening tool for kidney disease in patients from 1 to 25 years of age.
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